https://www.selleckchem.com/pr....oducts/netarsudil-ar
Overall, our findings indicated that ECT2 could be used as a promising new therapeutic candidate for PDAC.Doxorubicin (DOX) is a cytotoxic drug used for the treatment of breast cancer (BC). However, the rapid emergence of resistance toward doxorubicin threatens its clinical application, thus the need for combination therapy. Here, we interrogate the role of Emodin, a chemical compound with tumor inhibitory properties, in the resistance of BC to Doxorubicin. We first evaluated the efficacy of Emodin in the treatment of BC cel
Tycka om
Kommentar
Dela med sig
